Product logins

Find logins to all Clarivate products below.


In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast period, biosimilars are expected to enter the market and erode patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Related Market Assessment Reports

Report
Immunoglobulin A Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Growing momentum across both established and emerging therapies is reshaping the IgA nephropathy market as physicians balance established use of RAAS and SGLT2 inhibitors with adoption of newer…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
The schizophrenia therapy market remains highly competitive, dominated by atypical and typical antipsychotics. Ongoing generic erosion within the atypical class continues to shape psychiatrists’…
Report
Muscular Dystrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…